Mike Hennessy

Intricacies of translating these advances in our understanding of tumor biology into daily clinical practice are daunting in their own right.

Management of patients with CLL is entering a new era of precision medicine.

The big story in oncology research for the past several years has been the emergence of immunotherapy as a viable strategy for attacking many different tumor types.

There's no question that the advent of molecularly targeted strategies in anticancer therapy have revolutionized the understanding and practice of oncology, but it also is clear that those gains have not been uniformly realized throughout the range of malignancies.

The March issues of our oncology publications mark an exciting new era in the growth and maturity of our Oncology Specialty Group.

As 2010 has rolled along, the Intellisphere Oncology Specialty Group has aimed to uphold its mission of Bringing the Oncology Community Together.

In recent years, the buzzwords in oncology cancer have been "personalized therapy," in which the entire spectrum of cancer care is customized to the individual patient and his or her cancer.

Another year has come and gone, and it was a busy one for our group. We saw at least 10 new or expanded drug approvals for oncology products in 2010.

While family history and lifestyle factors affect cancer risk, environmental factors also play a considerable role. You will no doubt recall the movie Erin Brockovich, which recounted the story of a law firm file clerk uncovering the dumping of hexavalent chromium, also called chromium 6, into the groundwater supply of Hinkley, a small town in southern California, by Pacific Gas & Electric.